Factoid—BIIB’s $300M purchase of BMY’s anti-tau drug for AD is its biggest M&A transaction since the 2006 buyout of Fumapharm AG, the deal that netted Tecfidera (#msg-11358633).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.